MONOPOST is a prescription medication primarily used in the treatment of glaucoma and ocular hypertension. It belongs to a class of drugs known as prostaglandin analogs, which work by increasing the outflow of aqueous humor, the fluid in the eye, thereby reducing the intraocular pressure. This reduction in pressure can help prevent damage to the optic nerve, a common consequence of glaucoma that can lead to vision loss. MONOPOST is administered as an eye drop, making it a convenient option for patients. Its active ingredient is latanoprost, a well-studied compound known for its efficacy and safety profile. Patients prescribed MONOPOST must follow their healthcare provider's instructions closely to achieve the best outcomes and minimize side effects.